CIK 0001326732 · Accelerated filer
Xencor Inc
Sign in to watch- Ticker
- XNCR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 201622502
- Phone
- 626-305-5900
- Business address
- 465 N. HALSTEAD ST., SUITE 200, PASADENA, CA, 91107
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,591,617
- in 2 filings
Net −$3,591,617. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-05 | Valente Nancy EVP, Chief Development Officer | Grant or award | +19,634 | 59,860 | ||
| 2024-03-05 | Valente Nancy EVP, Chief Development Officer | Grant or award · Stock Options | +117,801 | 117,801 | ||
| 2024-03-05 | Kuch John J SR. VICE PRESIDENT & CFO | Sale | −4,474 | $23.43 | $105K | 121,919 |
| 2024-03-05 | Desjarlais John R SR. VICE PRESIDENT & CSO | Sale | −6,629 | $23.43 | $155K | 166,989 |
| 2024-03-05 | Desjarlais John R SR. VICE PRESIDENT & CSO | Grant or award | +20,724 | 187,713 | ||
| 2024-03-05 | Desjarlais John R SR. VICE PRESIDENT & CSO | Grant or award · Stock Options | +124,346 | 124,346 | ||
| 2024-03-05 | Eckert Celia SVP, GENERAL COUNSEL | Sale | −3,892 | $23.43 | $91K | 33,226 |
| 2024-03-05 | Eckert Celia SVP, GENERAL COUNSEL | Grant or award | +13,089 | 46,315 | ||
| 2024-03-05 | Eckert Celia SVP, GENERAL COUNSEL | Grant or award · Stock Options | +78,534 | 78,534 | ||
| 2024-03-05 | Dahiyat Bassil I PRESIDENT & CEO | Sale | −12,528 | $23.43 | $294K | 300,097 |
| 2024-03-05 | Dahiyat Bassil I PRESIDENT & CEO | Grant or award | +54,538 | 354,635 | ||
| 2024-03-05 | Dahiyat Bassil I PRESIDENT & CEO | Grant or award · Stock Options | +327,225 | 327,225 | ||
| 2024-02-14 | Desjarlais John R SR. VICE PRESIDENT & CSO | Option exercise | +11,943 | $11.05 | $132K | 173,618 |
| 2024-02-14 | Desjarlais John R SR. VICE PRESIDENT & CSO | Option exercise · Stock Option (Right to Buy) | −11,943 | 0 | ||
| 2024-02-13 | GORMAN KEVIN CHARLES Director | Purchase | +53 | $19.12 | $1K | 5,060 |
| 2024-02-13 | Desjarlais John R SR. VICE PRESIDENT & CSO | Option exercise | +68,057 | $11.05 | $752K | 215,783 |
| 2024-02-13 | Desjarlais John R SR. VICE PRESIDENT & CSO | Sale | −54,108 | $19.38 | $1.0M | 161,675 |
| 2024-02-13 | Desjarlais John R SR. VICE PRESIDENT & CSO | Option exercise · Stock Option (Right to Buy) | −68,057 | 11,943 | ||
| 2023-12-29 | Dahiyat Bassil I PRESIDENT & CEO | Option exercise | +65,001 | $11.05 | $718K | 357,929 |
| 2023-12-29 | Dahiyat Bassil I PRESIDENT & CEO | Sale | −45,000 | $20.93 | $942K | 312,929 |
Page 9 of 11 · 211 trades